IRCT20170303032845N1 IRCT 2019-02-03 Aracell zist daru The Comparison of Efficacy Between Iranian Made Ranibizumab and Imported Ranibizumab in Diabetic Patients with Macular Edema SVLD The Comparison of the Efficacy of Intravitreal Injection of Iranian Made Ranibizumab (Vicentis®) with Imported Ranibizumab (Lucentis®) in Patients with Diabetic Macular Edema: A phase III, Two-armed, Double-blind, Parallel, Active-controlled, and Noninferiority Clinical Randomized Trial 2019-12-22 anticipated 154 Complete https://irct.ir/trial/35718 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method: Block randomization Unit of Randomization: Individual Randomization tool: web-based software https://www.sealedenvelope.com/simple-randomiser/v1/lists, Blinding description: Both Ranibizumab drugs are indistinguishable for patients and the medical staff, and the only informed person is the nurse who is responsible for preparing the Ranibizumab according to the physician's instructions. Since Ranibizumab route of administration is intravitreal injection, it is possible to blind patients to the treatment groups. Additionally, people who evaluate the results and analyze data are not aware of the patients' group assignments. 3 Diabetic retinopathy. Intervention 1: Intervention group: An intravitreal injection of 0.05 ml Ranibizumab (Aracell zist daru). Intervention 2: Control group: An intravitreal injection of 0.05 ml Ranibizumab (Roche). No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information.